ClinicalTrials.gg
Active, not recruitingNCT04184050Updated Dec 5, 2025

Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001)

A Phase 1 interventional study of MK-4002 in Multiple Myeloma in Relapse, Multiple Myeloma and Multiple Myeloma of Bone, sponsored by Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). Active, not recruiting at 12 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-05.

Sponsored by Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
100
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 20 studies in Multiple Myeloma by Merck & Co., Inc — none open to participants now, 1 under way, none of them phase 3. Multiple Myeloma · Merck & Co., Inc.

Enrollment
9th of 20
100 · median 81
Started
2020
the only one that year
Phase 1
14 of 20
none open now
Registered
20th of 20
by date

Among the 20 studies in Multiple Myeloma by Merck & Co., Inc, this one is the 9th largest by enrollment, is the only one that started in 2020, is one of 14 in phase 1, and was the 20th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

None of the 20 studies in Multiple Myeloma by Merck & Co., Inc is open now. The open studies under Multiple Myeloma, anywhere →

Who these studies take

Of the 584 Multiple Myeloma studies recruiting now, 429 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 20 studies in Multiple Myeloma by Merck & Co., Inc as a file.
02

Study summary

Researchers want to learn if MK-4002 (also known as HPN217) can treat relapsed or refractory multiple myeloma (RRMM). The goals of this study are to learn about the safety of different doses of MK-4002 and how well people tolerate them. Researchers also want to learn what happens to different doses of MK-4002 in a person's body over time.

03

Conditions studied

  • Multiple Myeloma in Relapse
  • Multiple Myeloma
  • Multiple Myeloma of Bone
  • Multiple Myeloma With Failed Remission

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Major Inclusion Criteria:

  1. Patients ≥18 years of age at the time of signing
  2. Documented RRMM for which no standard therapy options are anticipated to result in a durable remission. Relapse defined as progressive disease after initial response (minimal response [MR] or better) to previous treatment, more than 60 days after cessation of last treatment. disease defined as \<25% reduction in M protein or progression of disease during treatment or within 60 days after cessation of treatment.
  3. Received at least 3 prior therapies (including proteasome inhibitor, immune modulatory drug, and an anti-CD38 antibody; patients should not be a candidate for or be intolerant of all established therapies known to provide clinical benefit in multiple myeloma).
  4. defined as at least one of the following:

    1. Serum M-protein ≥0.5 g/dL
    2. Urine M-protein ≥200 mg/24 hours
    3. Serum free light chain (FLC) assay: Involved FLC level ≥10 mg/dL (≥100 mg/L) and an abnormal serum FLC ratio (\<0.26 or >1.65)
  5. Resolved acute effects of any prior therapy to baseline severity or (CTCAE) version 5.0 Grade ≤1.

Major Exclusion Criteria:

  1. Plasma cell leukemia; non-secretory myeloma (e.g., solitary plasmacytoma)
  2. Patients with only extramedullary relapse of multiple myeloma who do not meet requirement for measurable disease.
  3. Prior peripheral stem cell transplant or prior autologous bone marrow transplantation within \<90 days of the start of study
  4. Prior allogeneic stem cell transplantation or solid organ transplantation within 12 months of Screening. However, any patient receiving medication will be excluded.
  5. History of or known or suspected disease (exception(s): patients with vitiligo, resolved childhood atopic dermatitis, hypothyroidism, or hyperthyroidism that is clinically euthyroid at Screening are allowed). Other exceptions may be allowed following discussion with the Sponsor Medical Monitor for patients who have not received any treatment for their autoimmune disorder in the past 3 years
  6. Second primary that has not been in remission for greater than 3 years. Exceptions that do not require a 3-year remission: non-melanoma skin cancer, resected melanoma in situ, in situ cervical cancer, adequately treated Stage I cancer from which the subject is currently in remission and has been in remission for ≥2 years, low-risk prostate cancer with Gleason score \<7 and prostate-specific antigen \<10 ng/mL
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    MK-4002 monotherapy dose escalation

    MK-4002 is intravenously (IV) administered once weekly in escalating doses.

    Drug: MK-4002

  • Experimental
    MK-4002 dose escalation with extended dosing intervals

    MK-4002 is IV administered once every 2 weeks.

    Drug: MK-4002

Interventions

  • DrugMK-4002

    IV infusion

    Also known as: HPN217

06

What researchers measure

Primary outcomes

  1. Number of Participants with Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) is defined as any untoward medical occurrence in a participant administered study drug, which does not necessarily have to have a causal relationship with the study drug. A TEAE is an adverse event that occurs on or after the first dose of study treatment. The number of participants with TEAEs graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 (American Society for Transplant and Cellular Therapy \[ASTCT\] grading criteria for cytokine release syndrome \[CRS\] and immune effector cell-associated neurotoxicity syndrome \[ICANS\]) will be reported.

    Time frame: Up to ~6 years

  2. Number of Participants Who Discontinued Study Treatment Due to an AE

    An AE is defined as any untoward medical occurrence in a participant administered study drug, which does not necessarily have to have a causal relationship with the study drug. The number of participants who discontinue study treatment due to an AE will be reported.

    Time frame: Up to ~6 years

  3. Number of Participants with Dose-limiting toxicities (DLT)

    A DLT is defined as an event with toxicity including the type, severity, time of onset, time of resolution, and the probable association with study treatment that are not due to pre-existing conditions as defined by the CTCAE 5.0 version for all AEs except CRS and ICANS, which will be graded according to ASTCT. The number of participants who experience a DLT will be reported.

    Time frame: Up to 35 days in Cycle 1

  4. Single Dose Maximum Serum Concentration (Cmax) of MK-4002

    Blood samples collected at designated time points will be used to determine the Cmax of MK-4002 after a single dose.

    Time frame: At designated timepoints (up to ~6 years)

  5. Single Dose Time to Maximum Concentration (Tmax) of MK-4002

    Blood samples collected at designated time points will be used to determine the Tmax of MK-4002 after a single dose.

    Time frame: At designated timepoints (up to ~6 years)

  6. Area Under the Single Dose Concentration-time Curve Over the Dosing Interval τ (AUCsd,τ) of MK-4002

    Blood samples collected at designated time points will be used to determine the AUCsd,τ of MK-4002.

    Time frame: At designated timepoints (up to ~6 years)

  7. Single Dose Area Under the Concentration-time Curve Extrapolated to Infinity (AUCinf) of MK-4002

    Blood samples collected at designated time points will be used to determine the AUCinf after a single dose of MK-4002.

    Time frame: At designated timepoints (up to ~6 years)

  8. Single Dose Terminal Elimination Half-life (t1/2) of MK-4002

    Blood samples collected at designated time points will be used to determine the t1/2 after a single dose of MK-4002.

    Time frame: At designated timepoints (up to ~6 years)

  9. Single Dose Clearance (CL) of MK-4002

    Blood samples collected at designated time points will be used to determine the CL after a single dose of MK-4002.

    Time frame: At designated timepoints (up to ~6 years)

  10. Multiple Dose Maximum Concentration at Steady State (Css,max) of MK-4002

    Blood samples collected at designated time points will be used to determine the Css,max of MK-4002. This outcome will be analyzed only if steady state is achieved, and data are available.

    Time frame: At designated timepoints (up to ~6 years)

  11. Multiple Dose Time to Maximum Concentration at Steady State (Tss,max) of MK-4002

    Blood samples collected at designated time points will be used to determine the Tss,max of MK-4002. This outcome will be analyzed only if steady state is achieved, and data are available.

    Time frame: At designated timepoints (up to ~6 years)

  12. Mutiple Dose Area Under the Steady State Concentration-time Curve Over the Dosing Interval τ (AUCss,τ) of MK-4002

    Blood samples collected at designated time points will be used to determine the (AUCss,τ) of MK-4002. This outcome will be analyzed only if steady state is achieved, and data are available.

    Time frame: At designated timepoints (up to ~6 years)

  13. Multiple Dose Terminal Elimination Half-life (t1/2) of MK-4002

    Blood samples collected at designated time points will be used to determine the t1/2 of MK-4002. This outcome will be analyzed only if steady state is achieved, and data are available.

    Time frame: At designated timepoints (up to ~6 years)

  14. Multiple Dose Minimum Concentration at Steady State (Css,min) of MK-4002

    Blood samples collected at designated time points will be used to determine the Css,min of MK-4002. This outcome will be analyzed only if steady state is achieved, and data are available.

    Time frame: At designated timepoints (up to ~6 years)

  15. Multiple Dose Clearance (CL)

    Blood samples collected at designated time points will be used to determine the CL of MK-4002. This outcome will be analyzed only if steady state is achieved, and data are available.

    Time frame: At designated timepoints (up to ~6 years)

  16. Multiple Dose Volume of Distribution at Steady State (Vss) of MK-4002

    Blood samples collected at designated time points will be used to determine the Vss of MK-4002. This outcome will be analyzed only if steady state is achieved, and data are available.

    Time frame: At designated timepoints (up to ~6 years)

  17. Multiple Dose Accumulation Ratio (AUCss,τ/AUCsd,τ) of MK-4002

    Blood samples collected at designated time points will be used to determine the (AUCss,τ/AUCsd,τ) of MK-4002. This outcome will be analyzed only if steady state is achieved, and data are available.

    Time frame: At designated timepoints (up to ~6 years)

Secondary outcomes

  1. Best Overall Response Rate (BOR)

    BOR is defined as the participant's best disease response assessed during the study. BOR will be based on assessments collected after the first dose of study drug until disease progression is documented.

    Time frame: Up to ~6 years

  2. Overall Response rate (ORR)

    ORR is defined as the percentage of the participants with either a stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR) according to the International Myeloma Working Group (IMWG) Response Criteria. CR = negative immunofixation of serum and urine AND \<5% plasma cells in the bone marrow; sCR = CR plus normal serum free light-chain (FLC) assay ratio and absence of clonal plasma cells in bone marrow; VGPR = serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥ 90% reduction in serum M-protein plus urine M-protein \<100 mg/24 hr; PR = ≥50% reduction of serum M- protein and reduction in 24-hour urinary M-protein by ≥90% or to \<200 mg/24 hours. The percentage of participants who experience CR or PR will be presented.

    Time frame: Up to ~6 years

  3. Progression-free Survival (PFS)

    PFS is defined as the time from first dose of study drug to documented disease progression or death due to any cause, whichever occurs first.

    Time frame: Up to ~6 years

  4. Overall Survival (OS)

    OS is defined as the time from first dose of study drug to death due to any cause.

    Time frame: Up to ~6 years

  5. Duration of Response (DOR)

    DOR is defined as the time from the first observed response observed response (sCR, CR, VGPR, or PR) to documented disease progression or death due to any cause. CR = negative immunofixation of serum and urine AND \<5% plasma cells in the bone marrow; sCR = CR plus normal serum free light-chain (FLC) assay ratio and absence of clonal plasma cells in bone marrow; VGPR = serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥ 90% reduction in serum M-protein plus urine M-protein \<100 mg/24 hr; PR = ≥50% reduction of serum M- protein and reduction in 24-hour urinary M-protein by ≥90% or to \<200 mg/24 hours. DOR as assessed by investigator according to IMWG response criteria will be presented.

    Time frame: Up to ~6 years

  6. Time to Response (TTR)

    TTR is defined as the time from first dose of study drug to the first observed response response (sCR, CR, VGPR, or PR). CR = negative immunofixation of serum and urine AND \<5% plasma cells in the bone marrow; sCR = CR plus normal serum free light-chain (FLC) assay ratio and absence of clonal plasma cells in bone marrow; VGPR = serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥ 90% reduction in serum M-protein plus urine M-protein \<100 mg/24 hr; PR = ≥50% reduction of serum M- protein and reduction in 24-hour urinary M-protein by ≥90% or to \<200 mg/24 hours. TTR as assessed by investigator according to IMWG response criteria will be presented.

    Time frame: Up to ~6 years

  7. Number of Participants with Anti-drug Antibodies (ADAs) against MK-4002

    Blood samples collected at designated time points will be used to determine the ADA response against MK-4002. The number of ADAs will be presented.

    Time frame: At designated timepoints (up to ~6 years)

  8. Titers of ADAs against MK-4002

    Blood samples collected at designated time points will be used to determine the titers of ADAs against MK-4002.

    Time frame: At designated timepoints (up to ~6 years)

  9. Percentage of Participants Who are Minimal Residual Disease (MRD) Negative

    Bone marrow samples will be used to determine the MRD negative. MRD is defined as the percentage of patients who achieve an sCR or CR who meet MRD Criteria for Sequencing MRD-negative rate at 10\^5 nucleated cells threshold and at 10\^6 nucleated cells threshold. CR = negative immunofixation of serum and urine AND \<5% plasma cells in the bone marrow; sCR = stringent complete response. Sequencing MRD-negative is the absence of clonal plasma cells by next-generation sequencing (NGS) on bone marrow aspirate in which presence of a clone is defined as less than 2 identical sequencing reads obtained after deoxyribonucleic acid (DNA) sequencing of bone marrow aspirates using the LymphoSIGHT platform (or validated equivalent method).

    Time frame: At designated timepoints (up to ~6 years)

07

Study locations

12 sites
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2020 (actual). Primary completion is estimated for Dec 2026, 80 months after the start.

Of 212 industry-sponsored phase 1 interventional studies under Multiple Myeloma, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 71. This study's planned 80 months is above that.

Counting every sponsor, half of 413 studies reached it within 50 months; a quarter within 33 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2019
First posted
Dec 3, 2019
StartActual
Apr 13, 2020
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Dec 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04184050
Responsible party
Sponsor
First posted
Dec 3, 2019
Start date
Apr 13, 2020
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Dec 5, 2025

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion